Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan OKs New Economic Package; Startup, Pharma Promotion Embraced
November 6, 2023
- FPMAJ Renews Call for Premium for Drugs Launched in Japan without Delay: LDP Confab
November 6, 2023
- Reward Innovation by Revisiting LLP Copay, Cut Doctor Fees: MOF
November 2, 2023
- Japan PM Pins Hope for Leadership of Kamoshita as Drug Policy Advisor
November 2, 2023
- MHLW to Consider Investigation on OTC Drug Abuse: Minister
November 2, 2023
- Organization to Push Drug Discovery Is One Option: Health Minister
November 1, 2023
- Basic Dementia Law Set to Take Effect on January 1: MHLW
November 1, 2023
- Japan Economic Package to Call for Boosting Innovation for Next-Gen Biologics
November 1, 2023
- Cases of Unintentional Xocova Use in Pregnant Women Total 32: MHLW
October 31, 2023
- AMED, Europe’s HERA to Cooperate in Medical Countermeasures
October 31, 2023
- PMDA Investigating Safety Risks of Eliquis, Other Anticoagulants for Acute Kidney Injury
October 30, 2023
- No Objections to Reflecting Company Indices for Generic Supplies in Pricing: Chuikyo
October 30, 2023
- Medical, Long-Term Care Data Linkage Holds Key to CEA: Leqembi Debate
October 30, 2023
- Panel OKs Xarelto’s Label Expansion for Post-Fontan Heart Failure Patients
October 30, 2023
- Lawmakers Demand NIP Coverage for Male Use of 4-Valent HPV Vaccine
October 26, 2023
- Japan’s Healthcare Spending Hits 45 Trillion Yen in FY2021
October 26, 2023
- Japan to Push 2024 Reform Debate by Using Price “Maintenance” and “Raise” Rules: PM
October 26, 2023
- Japan to Deliberate Pricing Measures for Stable Drug Supplies: Draft Economic Package
October 25, 2023
- Sawai’s Misconduct Severely Undermines Credibility of Generics: Health Minister
October 25, 2023
- Panel Approves Revision to Basic Blood Product Policy; Change to Take Effect Next April
October 24, 2023
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…